A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Creighton University · University of Arizona · +48 more institutions
Abstract
PURPOSE ATHENA (ClinicalTrials.gov identifier: NCT03522246 ) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics such as residual disease. We report the results from the ATHENA–MONO comparison of rucaparib versus placebo. METHODS Patients with stage III-IV high-grade ovarian cancer undergoing surgical cytoreduction (R0/complete resection permitted) and responding to first-line platinum-doublet chemotherapy were randomly assigned 4:1 to oral rucaparib 600 mg twice a day or placebo. Stratification factors were…
Citation impact
- FWCI
- 34.42
- Percentile
- 100%
- References
- 20
Authors
39- BJBradley J. MonkCorresponding
Creighton University, University of Arizona, HonorHealth
- CPChristine Parkinson
Addenbrooke's Hospital
- MCMyong Cheol Lim
National Cancer Center
- DMDavid M. O’Malley
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
- AOAna Oaknin
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
Topics & keywords
- Medicine
- Population
- Hazard ratio
- Internal medicine
- Ovarian cancer
- Clinical endpoint
- Placebo
- Oncology
- Good health and well-being